Winthrop

Manufactured by Sanofi

Sourced in Brazil, Morocco

Winthrop is a laboratory equipment product designed for various applications in research and clinical settings. It is a versatile and reliable tool that enables precise and efficient performance of laboratory tasks.

Automatically generated - may contain errors

Lab products found in correlation

Coartem, by Novartis (1 mentions)

Close spelling variants of this product

ASAQ Winthrop

3 protocols using winthrop

Efficacy and Safety of ASAQ vs CQ for Uncomplicated P. vivax

Check if the same lab product or an alternative is used in the 5 most similar protocols

This was an open-label, randomized, noninferiority, controlled trial that compared the efficacy and safety of ASAQ (Winthrop; Sanofi, Morocco) and CQ (Farmanguinhos, Brazil) for treatment of uncomplicated P. vivax blood stage infection. The study was based on the WHO antimalarial drug efficacy protocols modified for P. vivax [25 , 26 ]. Patients were followed up for 42 days to assess drug efficacy and safety.
The ethics review board of FMT-HVD (0426/2011) and the National Brazilian Committee of Ethics (16532/2011) approved the study. All adult patients and legal guardians of children provided written informed consent. The protocol is available in the Supplementary Materials.

Siqueira A.M., Alencar A.C., Melo G.C., Magalhaes B.L., Machado K., Alencar Filho A.C., Kuehn A., Marques M.M., Manso M.C., Felger I., Vieira J.L., Lameyre V., Daniel-Ribeiro C.T, & Lacerda M.V. (2016). Fixed-Dose Artesunate–Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 64(2), 166-174.

+ Open protocol

+ Expand

Dolutegravir Interactions with Antimalarials

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two open-label, fixed sequence studies between dolutegravir (Tivicay; ViiV Healthcare, Research Triangle Park, NC) given at 50 mg once daily and artemether-lumefantrine (Coartem; Novartis Pharma AG, Basel, Switzerland) (study A) or artesunate-amodiaquine (Winthrop; Sanofi-Aventis, Casablanca, Morocco) (study B) were conducted at the Infectious Diseases Institute, Kampala, Uganda (Fig. 3). Inclusion of 16 subjects in study A was calculated to have a >80% power to detect a change in AUC outside U.S. Food and Drug Administration (FDA) limits for bioequivalence (with the 90% CI for AUC falling within 80 to 125%) for dolutegravir and lumefantrine (assuming a coefficient of variation of ≤30%) and to detect a ≥32% change in dihydroartemisinin levels. Including 30 subjects in study B would yield an 80% power to detect an AUC difference of >25% to 30% (DTG and DEAQ), and a ≥42% change for dihydroartemisinin.

Walimbwa S.I., Lamorde M., Waitt C., Kaboggoza J., Else L., Byakika-Kibwika P., Amara A., Gini J., Winterberg M., Chiong J., Tarning J, & Khoo S.H. (2019). Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Antimicrobial Agents and Chemotherapy, 63(2), e01310-18.

+ Open protocol

+ Expand

Vitamin D2 Supplementation in Adults

Check if the same lab product or an alternative is used in the 5 most similar protocols

This study was a 24-week randomized, double-blind, placebocontrolled, single-center clinical trial. Using block randomization with random block size, subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop [Sanofi-Aventis]) or placebo, given at baseline and 12 weeks [14] . Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Capsules were taken with milk to optimize absorption.
Height, weight, and BMI were obtained at baseline, 12 weeks, and 24 weeks. Fasting morning blood samples were obtained at each visit for measurement of serum 25OHD, intact parathyroid hormone (iPTH), calcium, phosphorus, alkaline phosphatase, glucose, high-density lipoprotein, triglycerides, hs-CRP, IL-6, IL-10, TNF-a, and adiponectin. Serum magnesium and hemoglobin A1C were measured at baseline and 24 weeks. Subjects with serum 25OHD concentration of <10 ng/mL at any time point were removed from the study and treated for vitamin D deficiency.

Shah S., Wilson D.M, & Bachrach L.K. (2015). Large Doses of Vitamin D Fail to Increase 25-Hydroxyvitamin D Levels or to Alter Cardiovascular Risk Factors in Obese Adolescents: A Pilot Study. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 57(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!